Skip to main content

Edwards Lifesciences Corp Value Stock - Dividend - Research Selection

Edwards lifesciences

ISIN: US28176E1082 , WKN: 936853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?

2026-05-28
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Josh Brown's 'best stocks in the market': Edwards Lifesciences

2026-05-28
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail Ritholt's new "Porterhouse" strategy. Josh also spotlights Edwards Lifesciences in his "Best Stocks in the Market."

Is Edwards Lifesciences (EW) Fairly Priced After Recent Share Price Strength?

2026-05-28
Wondering if Edwards Lifesciences at around US$86.51 is offering good value today, or if the recent share price leaves little margin for error. The stock has returned 4.3% over the last week, 3.7% over the past month, 1.4% year to date, and 12.8% over the past year, while the 3 year return sits at 2.7% and the 5 year return shows a decline of 7.4%. Recent coverage has focused on Edwards Lifesciences as a key player in medical equipment, with attention on how its products fit into long term...

Edwards Lifesciences Has Everything Investors Want Except Value

2026-05-27
Edwards Lifesciences remains a high-quality business with a wide economic moat , but the stock is still overvalued. Click here to read more on the EW stock.

Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth

2026-05-26
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.

Tulyp Medical Appoints Industry Veteran Steve Motes as CEO to Lead Next Phase of Growth in the US

2026-05-18
PARIS & DALLAS, May 18, 2026--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study.

VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer

2026-05-18
SANTA CLARA, Calif., May 18, 2026--VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer.

Are Wall Street Analysts Bullish on Edwards Lifesciences Stock?

2026-05-14
While Edwards Lifesciences has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings

2026-05-13
Soft earnings didn't appear to concern Edwards Lifesciences Corporation's ( NYSE:EW ) shareholders over the last week...

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

2026-05-12
Edwards Lifesciences Corporation (EW) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDTCompany ParticipantsBernard Zovighian - CEO...